Health
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine – News-Medical.Net
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being…
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The vaccine comprises a recombinant adenovirus serotype 26 (Ad26) vaccine vector expressing a stabilized form of the SARS-CoV-2 spike antigen that the…
-
Noosa News23 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
General19 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General12 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
General22 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity